Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vortioxetine - Lundbeck

Next Previous
Drug Profile

Vortioxetine - Lundbeck

Alternative Names: Brintellix; LU-AA21004; LuAA 21004; Trintellix; VORTIDIF; vortioxetine-hydrobromide

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Seoul National University Hospital; Takeda; University of Chicago
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Piperazines; Small molecules; Sulfides
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Anxiety disorders; Binge-eating disorder; Bipolar depression
  • Discontinued Attention-deficit hyperactivity disorder; Generalised anxiety disorder

Most Recent Events

  • 01 Oct 2025 Takeda plans a phase III trial for Major depressive disorder (In Children, In Adolescents) in Japan (PO, Tablets) (NCT07204314)
  • 11 Dec 2024 No development reported - Phase-III for Major depressive disorder (In adolescents, In children) in Denmark, Estonia, France, Hungary, Italy, Latvia, Poland, Russia, Serbia, Spain, South Africa, United Kingdom (PO)
  • 18 Oct 2022 Efficacy and adverse events data from a phase III MEMORY trial in Major depressive disorder released by Lundbeck

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top